DOCSLIB.ORG

Table 1. Antibodies Used for Chromatin Immunoprecipitation (Chip)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Table 1. Antibodies Used for Chromatin Immunoprecipitation (Chip) Table 1. Antibodies used for chromatin immunoprecipitation (ChIP) Protein Antibody Manufacturer References Western blot ChIP p65 sc-372 Santa Cruz (1, 2) (3-5) Biotechnology p50 sc-1190 Santa Cruz (6) (7) Biotechnology RelB sc-226 Santa Cruz (8) (5) Biotechnology c-Rel sc-71 Santa Cruz (8) (5, 9) Biotechnology p52 06-413 Upstate Biotechnology, (10) Lake Placid, NY E2F4 sc-1082 Santa Cruz (11) (12) Biotechnology Pol II 8WG16 (13) (14) The fact that the p65 dataset has no targets in unstimulated cells confirms the lack of background enrichment from the Dynal magnetic beads. The number of p50 targets in unstimulated cells is higher than for the other subunits. We were concerned that this might be due to the antibody used. Therefore, we tested another antibody raised against the N-terminus of the protein (sc-1191). In test experiments, 90% of enriched gene promoters were shared between the two p50 antibodies (data not shown). 1. Rodriguez, M. S., Thompson, J., Hay, R. T. & Dargemont, C. (1999) J. Biol. Chem. 274, 9108-9115. 2. Huang, T. T., Kudo, N., Yoshida, M. & Miyamoto, S. (2000) Proc. Natl. Acad. Sci. USA 97, 1014-1019. 3. Nissen, R. M. & Yamamoto, K. R. (2000) Genes Dev. 14, 2314-2329. 4. Martone, R., Euskirchen, G., Bertone, P., Hartman, S., Royce, T. E., Luscombe, N. M., Rinn, J. L., Nelson, F. K., Miller, P., Gerstein, M., et al. (2003) Proc. Natl. Acad. Sci. USA 100, 12247-12252. 5. Saccani, S., Pantano, S. & Natoli, G. (2003) Mol. Cell 11, 1563-1574. 6. Yamazaki, T. & Kurosaki, T. (2003) Nat. Immunol 4, 780-786. 7. Baek, S. H., Ohgi, K. A., Rose, D. W., Koo, E. H., Glass, C. K. & Rosenfeld, M. G. (2002) Cell 110, 55-67. 8. Wang, W., Tam, W. F., Hughes, C. C., Rath, S. & Sen, R. (1997) Immunity 6, 165-174. 9. Liu, J. & Beller, D. I. (2003) J. Immunol. 170, 4489-4496. 10. Senftleben, U., Cao, Y., Xiao, G., Greten, F. R., Krahn, G., Bonizzi, G., Chen, Y., Hu, Y., Fong, A., Sun, S. C. & Karin, M. (2001) Science 293, 1495-1499. 11. Takahashi, Y., Rayman, J. B. & Dynlacht, B. D. (2000) Genes Dev. 14, 804-816. 12. Ren, B., Cam, H., Takahashi, Y., Volkert, T., Terragni, J., Young, R. A. & Dynlacht, B. D. (2002) Genes Dev. 16, 245-256. 13. Hirakata, M., Okano, Y., Pati, U., Suwa, A., Medsger, T. A., Jr., Hardin, J. A. & Craft, J. (1993) J. Clin. Invest. 91, 2665-2672. 14. Odom, D. T., Zizlsperger, N., Gordon, D. B., Bell, G. W., Rinaldi, N. J., Murray, H. L., Volkert, T. L., Schreiber, J., Rolfe, P. A., Gifford, D. K., et al. (2004) Science 303, 1378- 1381. Table 2. Gene ontology (GO) categories enriched in the set of genes bound by NF-κB GO system GO category Number of Total number P value bound genes of genes in category Biological process Response to biotic stimulus 44 516 6.3E-07 Biological process Immune response 38 425 1.3E-06 Biological process Defense response 39 475 7.8E-06 Biological process Response to pest/pathogen/parasite 26 276 3E-05 Molecular function Cytokine activity 15 133 0.00011 Molecular function Transcription factor activity 32 468 0.00046 Biological process Response to stress 33 465 0.00068 Biological process Response to wounding 16 163 0.0007 Molecular function Tumor necrosis factor receptor binding 4 12 0.00072 Biological process Response to external stimulus 49 793 0.00083 Molecular function Transcription regulator activity 38 635 0.00172 Biological process Antigen processing, endogenous 3 7 0.00193 antigen via MHC class I Biological process Inflammatory response 12 116 0.00207 Molecular function Receptor binding 23 332 0.00255 Biological process Antigen processing 3 8 0.003 Biological process Response to stimulus 53 934 0.00345 Biological process Transcription 50 869 0.00347 Biological process Innate immune response 12 125 0.00387 Biological process Regulation of transcription from Pol II 13 143 0.0043 promoter Biological process Response to virus 5 28 0.00442 Molecular function GTP binding 12 139 0.00517 Molecular function Chemokine receptor binding 5 32 0.00592 Molecular function Chemokine activity 5 32 0.00592 Molecular function Guanyl nucleotide binding 12 143 0.00648 Molecular function G-protein-coupled receptor binding 5 33 0.00677 Biological process Transcription, DNA-dependent 47 833 0.00681 Biological process Cell motility 14 169 0.00707 Biological process Viral life cycle 4 20 0.00714 Molecular function DNA binding 48 930 0.00858 Biological process Transcription from Pol II promoter 20 285 0.00902 Molecular function Binding 149 3,561 0.0091 Fisher exact scores were generated using the EASEonline tool (aaps1.niaid.nih.gov/david). A total of 5,707 genes present of the arrays were annotated by GO biological process information; 227 of these were bound by NF-κB. Table 3. Genes bound by NF-κB in U937 cells EntrezGene Description + LPS - LPS Known targets symbol p65 c-Rel RelB p50 p52 p65 c-Rel RelB p50 p52 ABHD8 hypothetical protein FLJ11743 + ACTR3 ARP3 actin-related protein 3 homolog + + AF093680 similar to mouse Glt3 + w AF15Q14 AF15q14 protein + w AIM2 absent in melanoma 2 + + + + + ALAS1 aminolevulinate, delta-, synthase 1 + + + + + AP1S2 adaptor-related protein complex 1 + w + + APBB1IP similar to proline-rich protein 48 + + + + + APG-1 heat shock protein (hsp110 family) w + AQP9 aquaporin 9 + + + + + ARF3 ADP-ribosylation factor 3 + + + + ARHGAP4 Rho GTPase activating protein 4 + w ARHGEF2 rho/rac guanine nucleotide exchange factor + + + + + + ARL1 ADP-ribosylation factor-like 1 + + + X ARL6IP5 vitamin A responsive; cytoskeleton related + + w + w ARTS-1 type 1 TNFR shedding aminopeptidase regulator + + ASGR2 asialoglycoprotein receptor 2 + ASH1 hypothetical protein ASH1 + + + + ATF6 activating transcription factor 6 + w ATP5G1 ATP synthase, H+ transporting + w BAT3 HLA-B associated transcript 3 w + BAZ1B bromodomain adjacent to zinc finger domain, 1B + w BCL2A1 BCL2-related protein A1 + + + + w X BCL6 B-cell CLL/lymphoma 6 (zinc finger protein 51) + w BF B-factor, properdin + w X BNIP1 BCL2/adenovirus E1B 19kD interacting protein 1 + + + BPI bactericidal/permeability-increasing protein + C10orf117 AD24 protein + C11orf10 chromosome 11 open reading frame 10 + w C14orf111 CGI-35 protein + + C20orf28 chromosome 20 open reading frame 28 + C21orf45 chromosome 21 open reading frame 45 + + C21orf59 chromosome 21 open reading frame 59 w + + C3 complement component 3 + + + + w + X C6orf109 DKFZP566C243 protein + + C6orf66 HSPC125 protein + w + + C7orf10 chromosome 7 open reading frame 10 + + + C9orf100 hypothetical protein FLJ14642 + w + + CA11 carbonic anhydrase XI + + + + CAPZA1 capping protein (actin filament) muscle Z-line + CARD15 caspase recruitment domain family, member 15 + X CAT catalase + + CCDC2 capillary morphogenesis protein 1 + CCL1 small inducible cytokine A1, I-309 + + + + X CCL3 small inducible cytokine A3, Mip-1-alpha + + + + + + + + X CCL4 small inducible cytokine A4, Mip-1-beta + + + + w + X CCL5 small inducible cytokine A5 (RANTES) w w + + + X CCNL1 cyclin L ania-6a + + + + + + + + CCR1 chemokine (C-C motif) receptor 1 + w CCRL2 chemokine (C-C motif) receptor-like 2 + + + + w CD37 CD37 antigen w + CD58 CD58 antigen, (LFA 3) w + + CD69 CD69 antigen (p60, early T-cell activation antigen) w + + + + X CDCA1 cell division cycle associated 1 + w w CDH15 cadherin 15, M-cadherin (myotubule) + + CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) + X CHI3L2 chitinase 3-like 2 w + + + CLCN1 chloride channel 1, skeletal muscle (Thomsen disease) w + CLECSF14 macrophage lectin 2 (calcium dependent) + + w COX4I1 cytochrome c oxidase subunit IV isoform 1 + + CREB1 cAMP responsive element binding protein 1 + + + + + + + CRYBA1 crystallin, beta A1 + CSF2 colony stimulating factor 2 (granulocyte-macrophage) + + + + + X CSF3 colony stimulating factor 3 (granulocyte) + + w X CST7 cystatin F (leukocystatin) + w CTSC cathepsin C + + CYB5 cytochrome b-5 + w CYP51A1 cytochrome P450, 51 (lanosterol 14-alpha-demethylase) + DAF decay accelerating factor for complement + + + + + + DBI diazepam binding inhibitor (GABA receptor modulator) + + + + + DBP D site of albumin promoter binding protein + DDX21 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 21 + DDX31 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 31 + DDX47 hqp0256 protein w + + + DGCR6L DiGeorge syndrome critical region gene 6 like + DGUOK deoxyguanosine kinase + DJ434O14.3 hypothetical protein dJ434O14.3 + DKFZp434K1210 hypothetical protein DKFZp434K1210 + + + + DKFZp762L0311 hypothetical protein DKFZp762L0311 + + + Entrez Gene Description + LPS - LPS Known targets symbol p65 c-Rel RelB p50 p52 p65 c-Rel RelB p50 p52 DMAP1 DNA methyltransferase 1-associated protein 1 w + + DPP3 dipeptidylpeptidase III w + + DR1 down-regulator of transcription 1, TBP-binding + + DXS9879E DNA segment on chromosome X, expressed sequence + + EFEMP2 EGF-containing fibulin-like extracellular matrix protein 2 w + EFNB1 ephrin-B1 + + EIF2S3 eukaryotic translation initiation factor 2, subunit 3 w + + + + + ELF3 E74-like factor 3 (ets domain transcription factor) + X ELK1 ELK1, member of ETS oncogene family + EMP3 epithelial membrane protein 3 + + + + ERBB2IP erbb2 interacting protein + + + w ERCC1 excision repair cross-complementing repair deficiency + ET hypothetical protein ET w + EXTL2 exostoses (multiple)-like 2 + + FBXW3 F-box and WD-40 domain protein 3 + X FCAR Fc fragment of IgA, receptor for + + + + FEN1 flap structure-specific endonuclease 1 + + + + FHL3 four and a half LIM domains 3 + + w + w FIBP fibroblast growth factor (acidic) intracellular binding protein + + FKSG87 FKSG87 protein + + + FLJ10420 hypothetical protein FLJ10420 + + + + w FLJ10687 hypothetical
Load more

Recommended publications
  • Remodeling Adipose Tissue Through in Silico Modulation of Fat Storage For
    Chénard et al. BMC Systems Biology (2017) 11:60 DOI 10.1186/s12918-017-0438-9 RESEARCHARTICLE Open Access Remodeling adipose tissue through in silico modulation of fat storage for the prevention of type 2 diabetes Thierry Chénard2, Frédéric Guénard3, Marie-Claude Vohl3,4, André Carpentier5, André Tchernof4,6 and Rafael J. Najmanovich1* Abstract Background: Type 2 diabetes is one of the leading non-infectious diseases worldwide and closely relates to excess adipose tissue accumulation as seen in obesity. Specifically, hypertrophic expansion of adipose tissues is related to increased cardiometabolic risk leading to type 2 diabetes. Studying mechanisms underlying adipocyte hypertrophy could lead to the identification of potential targets for the treatment of these conditions. Results: We present iTC1390adip, a highly curated metabolic network of the human adipocyte presenting various improvements over the previously published iAdipocytes1809. iTC1390adip contains 1390 genes, 4519 reactions and 3664 metabolites. We validated the network obtaining 92.6% accuracy by comparing experimental gene essentiality in various cell lines to our predictions of biomass production. Using flux balance analysis under various test conditions, we predict the effect of gene deletion on both lipid droplet and biomass production, resulting in the identification of 27 genes that could reduce adipocyte hypertrophy. We also used expression data from visceral and subcutaneous adipose tissues to compare the effect of single gene deletions between adipocytes from each
    [Show full text]
  • Methods for Identifying Circadian Rhythm
    (19) *EP003302716B1* (11) EP 3 302 716 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61Q 17/04 (2006.01) G01N 33/50 (2006.01) (2006.01) (2006.01) 14.10.2020 Bulletin 2020/42 A61Q 19/08 A61Q 19/00 C12Q 1/68 (2018.01) (21) Application number: 16729482.6 (86) International application number: (22) Date of filing: 08.06.2016 PCT/US2016/036401 (87) International publication number: WO 2016/200905 (15.12.2016 Gazette 2016/50) (54) METHODS FOR IDENTIFYING CIRCADIAN RHYTHM-DEPENDENT COSMETIC AGENTS FOR SKIN CARE COMPOSITIONS VERFAHREN ZUR IDENTIFIZIERUNG VON BIORHYTHMUSABHÄNGIGEN KOSMETISCHEN MITTELN FÜR HAUTPFLEGEZUSAMMENSETZUNGEN PROCÉDÉS D’IDENTIFICATION D’AGENTS COSMÉTIQUES DÉPENDANT DU RYTHME CIRCADIEN POUR DES COMPOSITIONS DE SOIN DE LA PEAU (84) Designated Contracting States: • OSBORNE, Rosemarie AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Cincinnati, Ohio 45202 (US) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: P&G Patent Belgium UK N.V. Procter & Gamble Services Company S.A. (30) Priority: 08.06.2015 US 201562172498 P Temselaan 100 1853 Strombeek-Bever (BE) (43) Date of publication of application: 11.04.2018 Bulletin 2018/15 (56) References cited: WO-A1-2010/079285 JP-A- 2010 098 965 (73) Proprietor: The Procter & Gamble Company US-A1- 2009 220 481 US-A1- 2010 028 317 Cincinnati, OH 45202 (US) US-A1- 2015 071 895 (72) Inventors: • GEYFMAN MIKHAIL ET AL: "Clock genes, hair • MULLINS, Lisa, Ann growth and aging", AGING, NEW YORK, NY, US, Cincinnati, Ohio 45202 (US) vol.
    [Show full text]
  • An Order Estimation Based Approach to Identify Response Genes
    AN ORDER ESTIMATION BASED APPROACH TO IDENTIFY RESPONSE GENES FOR MICRO ARRAY TIME COURSE DATA A Thesis Presented to The Faculty of Graduate Studies of The University of Guelph by ZHIHENG LU In partial fulfilment of requirements for the degree of Doctor of Philosophy September, 2008 © Zhiheng Lu, 2008 Library and Bibliotheque et 1*1 Archives Canada Archives Canada Published Heritage Direction du Branch Patrimoine de I'edition 395 Wellington Street 395, rue Wellington Ottawa ON K1A0N4 Ottawa ON K1A0N4 Canada Canada Your file Votre reference ISBN: 978-0-494-47605-5 Our file Notre reference ISBN: 978-0-494-47605-5 NOTICE: AVIS: The author has granted a non­ L'auteur a accorde une licence non exclusive exclusive license allowing Library permettant a la Bibliotheque et Archives and Archives Canada to reproduce, Canada de reproduire, publier, archiver, publish, archive, preserve, conserve, sauvegarder, conserver, transmettre au public communicate to the public by par telecommunication ou par Plntemet, prefer, telecommunication or on the Internet, distribuer et vendre des theses partout dans loan, distribute and sell theses le monde, a des fins commerciales ou autres, worldwide, for commercial or non­ sur support microforme, papier, electronique commercial purposes, in microform, et/ou autres formats. paper, electronic and/or any other formats. The author retains copyright L'auteur conserve la propriete du droit d'auteur ownership and moral rights in et des droits moraux qui protege cette these. this thesis. Neither the thesis Ni la these ni des extraits substantiels de nor substantial extracts from it celle-ci ne doivent etre imprimes ou autrement may be printed or otherwise reproduits sans son autorisation.
    [Show full text]
  • RFXANK Mouse Monoclonal Antibody [Clone ID: OTI3C10] – TA504261
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TA504261 RFXANK Mouse Monoclonal Antibody [Clone ID: OTI3C10] Product data: Product Type: Primary Antibodies Clone Name: OTI3C10 Applications: FC, IF, IHC, WB Recommended Dilution: WB 1:500, IHC 1:150, IF 1:100, FLOW 1:100 Reactivity: Human, Mouse, Rat Host: Mouse Isotype: IgG1 Clonality: Monoclonal Immunogen: Full length human recombinant protein of human RFXANK(NP_604389) produced in HEK293T cell. Formulation: PBS (PH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide. Concentration: 1 mg/ml Purification: Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G) Conjugation: Unconjugated Storage: Store at -20°C as received. Stability: Stable for 12 months from date of receipt. Predicted Protein Size: 25.4 kDa Gene Name: regulatory factor X associated ankyrin containing protein Database Link: NP_604389 Entrez Gene 8625 Human O14593 This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 3 RFXANK Mouse Monoclonal Antibody [Clone ID: OTI3C10] – TA504261 Background: Major histocompatibility (MHC) class II molecules are transmembrane proteins that have a central role in development and control of the immune system. The protein encoded by this gene, along with regulatory factor X-associated protein and regulatory factor-5, forms a complex that binds to the X box motif of certain MHC class II gene promoters and activates their transcription.
    [Show full text]
  • Table S1. 49 Histone Variants Were Identified with High Sequence Coverage Through LC-MS/MS Analysis Electronic Supplementary
    Electronic Supplementary Material (ESI) for Analytical Methods. This journal is © The Royal Society of Chemistry 2020 Table S1. 49 histone variants were identified with high sequence coverage through LC-MS/MS analysis Sequence Uniprot IDs Protein Name Protein Description Coverage Ratio E2+/E2- RSD P07305 H10_HUMAN 67.5% Histone H1.0 OS=Homo sapiens GN=H1F0 PE=1 SV=3 4.85 23.3% Histone H1.1 OS=Homo sapiens GN=HIST1H1A PE=1 Q02539 H11_HUMAN 74.4% SV=3 0.35 92.6% Histone H1.2 OS=Homo sapiens GN=HIST1H1C PE=1 P16403 H12_HUMAN 67.1% SV=2 0.73 80.6% Histone H1.3 OS=Homo sapiens GN=HIST1H1D PE=1 P16402 H13_HUMAN 63.8% SV=2 0.75 77.7% Histone H1.4 OS=Homo sapiens GN=HIST1H1E PE=1 P10412 H14_HUMAN 69.0% SV=2 0.70 80.3% Histone H1.5 OS=Homo sapiens GN=HIST1H1B PE=1 P16401 H15_HUMAN 79.6% SV=3 0.29 98.3% Testis-specific H1 histone OS=Homo sapiens GN=H1FNT Q75WM6 H1FNT_HUMAN 7.8% \ \ PE=2 SV=3 Histone H1oo OS=Homo sapiens GN=H1FOO PE=2 Q8IZA3 H1FOO_HUMAN 5.2% \ \ SV=1 Histone H1t OS=Homo sapiens GN=HIST1H1T PE=2 P22492 H1T_HUMAN 31.4% SV=4 1.42 65.0% Q92522 H1X_HUMAN 82.6% Histone H1x OS=Homo sapiens GN=H1FX PE=1 SV=1 1.15 33.2% Histone H2A type 1 OS=Homo sapiens GN=HIST1H2AG P0C0S8 H2A1_HUMAN 99.2% PE=1 SV=2 0.57 26.8% Q96QV6 H2A1A_HUMAN 58.0% Histone H2A type 1-A OS=Homo sapiens 0.90 11.2% GN=HIST1H2AA PE=1 SV=3 Histone H2A type 1-B/E OS=Homo sapiens P04908 H2A1B_HUMAN 99.2% GN=HIST1H2AB PE=1 SV=2 0.92 30.2% Histone H2A type 1-C OS=Homo sapiens Q93077 H2A1C_HUMAN 100.0% GN=HIST1H2AC PE=1 SV=3 0.76 27.6% Histone H2A type 1-D OS=Homo sapiens P20671
    [Show full text]
  • KIAA0101/P15paf) Over Expression and Gene Copy Number Alterations in Hepatocellular Carcinoma Tissues
    PCNA-associated Factor (KIAA0101/p15PAF) over expression and Gene Copy Number Alterations in Hepatocellular Carcinoma Tissues Anchalee Tantiwetrueangdet Research Center, Faculty of Medicine, Ramathibodi Hospital Ravat Panvichian ( [email protected] ) Mahidol University Faculty of Medicine Ramathibodi Hospital https://orcid.org/0000-0001-5282-8166 Pattana Sornmayura Department of Pathology, Faculty of Medicine, Ramathibodi Hospital Surasak Leelaudomlipi Department of Surgery, Faculty of Medicine, Ramathibodi Hospital Research article Keywords: PCNA-associated factor (KIAA0101/p15PAF), droplet digital PCR, real-time PCR, p53 tumor suppressor protein, Ki-67 proliferation marker protein, HCC DOI: https://doi.org/10.21203/rs.3.rs-39782/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/18 Abstract Background PCNA-associated factor (KIAA0101/p15PAF) is a cell-cycle regulated oncoprotein that regulates DNA synthesis, maintenance of DNA methylation, and DNA-damage bypass, through the interaction with the human sliding clamp PCNA. KIAA0101 is overexpressed in various cancers, including hepatocellular carcinoma (HCC). However, it remains unknown whether KIAA0101 gene ampliƒcation occurs and causally correlates with the KIAA0101 overexpression in HCC. This question is relevant to the development of the optimal test(s) for KIAA0101 and the strategies to target KIAA0101 in HCC. Methods In this study, we validated KIAA0101 mRNA expression levels by quantitative real-time PCR in 40 pairs of snap-frozen HCC and matched-non-cancerous tissues; we then evaluated KIAA0101 gene copy numbers by droplet digital PCR (ddPCR) in 36 pairs of the tissues. Besides, KIAA0101 protein expression was detected by immunohistochemistry (IHC) in 81 pairs of formalin-ƒxed para∆n-embedded (FFPE) tissues.
    [Show full text]
  • A Cell Line P53 Mutation Type UM
    A Cell line p53 mutation Type UM-SCC 1 wt UM-SCC5 Exon 5, 157 GTC --> TTC Missense mutation by transversion (Valine --> Phenylalanine UM-SCC6 wt UM-SCC9 wt UM-SCC11A wt UM-SCC11B Exon 7, 242 TGC --> TCC Missense mutation by transversion (Cysteine --> Serine) UM-SCC22A Exon 6, 220 TAT --> TGT Missense mutation by transition (Tyrosine --> Cysteine) UM-SCC22B Exon 6, 220 TAT --> TGT Missense mutation by transition (Tyrosine --> Cysteine) UM-SCC38 Exon 5, 132 AAG --> AAT Missense mutation by transversion (Lysine --> Asparagine) UM-SCC46 Exon 8, 278 CCT --> CGT Missense mutation by transversion (Proline --> Alanine) B 1 Supplementary Methods Cell Lines and Cell Culture A panel of ten established HNSCC cell lines from the University of Michigan series (UM-SCC) was obtained from Dr. T. E. Carey at the University of Michigan, Ann Arbor, MI. The UM-SCC cell lines were derived from eight patients with SCC of the upper aerodigestive tract (supplemental Table 1). Patient age at tumor diagnosis ranged from 37 to 72 years. The cell lines selected were obtained from patients with stage I-IV tumors, distributed among oral, pharyngeal and laryngeal sites. All the patients had aggressive disease, with early recurrence and death within two years of therapy. Cell lines established from single isolates of a patient specimen are designated by a numeric designation, and where isolates from two time points or anatomical sites were obtained, the designation includes an alphabetical suffix (i.e., "A" or "B"). The cell lines were maintained in Eagle's minimal essential media supplemented with 10% fetal bovine serum and penicillin/streptomycin.
    [Show full text]
  • Herpes Simplex Virus Blocks Host Transcription Termination Via the Bimodal Activities of ICP27
    ARTICLE https://doi.org/10.1038/s41467-019-14109-x OPEN Herpes simplex virus blocks host transcription termination via the bimodal activities of ICP27 Xiuye Wang 1, Thomas Hennig2, Adam W. Whisnant 2, Florian Erhard 2, Bhupesh K. Prusty 2, Caroline C. Friedel 3, Elmira Forouzmand4,5, William Hu1, Luke Erber 6, Yue Chen6, Rozanne M. Sandri-Goldin 1*, Lars Dölken 2,7* & Yongsheng Shi1* Infection by viruses, including herpes simplex virus-1 (HSV-1), and cellular stresses cause 1234567890():,; widespread disruption of transcription termination (DoTT) of RNA polymerase II (RNAPII) in host genes. However, the underlying mechanisms remain unclear. Here, we demonstrate that the HSV-1 immediate early protein ICP27 induces DoTT by directly binding to the essential mRNA 3’ processing factor CPSF. It thereby induces the assembly of a dead-end 3’ processing complex, blocking mRNA 3’ cleavage. Remarkably, ICP27 also acts as a sequence- dependent activator of mRNA 3’ processing for viral and a subset of host transcripts. Our results unravel a bimodal activity of ICP27 that plays a key role in HSV-1-induced host shutoff and identify CPSF as an important factor that mediates regulation of transcription termination. These findings have broad implications for understanding the regulation of transcription termination by other viruses, cellular stress and cancer. 1 Department of Microbiology and Molecular Genetics, School of Medicine, University of California, Irvine, Irvine, CA 92697, USA. 2 Institute for Virology and Immunobiology, Julius-Maximilians-University Würzburg, Würzburg, Germany. 3 Institute of Informatics, Ludwig-Maximilians-Universität München, München, Germany. 4 Institute for Genomics and Bioinformatics, University of California, Irvine, Irvine, CA 92697, USA.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • 4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation
    Methods Mice: 4-6 weeks old female C57BL/6 mice obtained from Jackson labs were used for cell isolation. Female Foxp3-IRES-GFP reporter mice (1), backcrossed to B6/C57 background for 10 generations, were used for the isolation of naïve CD4 and naïve CD8 cells for the RNAseq experiments. The mice were housed in pathogen-free animal facility in the La Jolla Institute for Allergy and Immunology and were used according to protocols approved by the Institutional Animal Care and use Committee. Preparation of cells: Subsets of thymocytes were isolated by cell sorting as previously described (2), after cell surface staining using CD4 (GK1.5), CD8 (53-6.7), CD3ε (145- 2C11), CD24 (M1/69) (all from Biolegend). DP cells: CD4+CD8 int/hi; CD4 SP cells: CD4CD3 hi, CD24 int/lo; CD8 SP cells: CD8 int/hi CD4 CD3 hi, CD24 int/lo (Fig S2). Peripheral subsets were isolated after pooling spleen and lymph nodes. T cells were enriched by negative isolation using Dynabeads (Dynabeads untouched mouse T cells, 11413D, Invitrogen). After surface staining for CD4 (GK1.5), CD8 (53-6.7), CD62L (MEL-14), CD25 (PC61) and CD44 (IM7), naïve CD4+CD62L hiCD25-CD44lo and naïve CD8+CD62L hiCD25-CD44lo were obtained by sorting (BD FACS Aria). Additionally, for the RNAseq experiments, CD4 and CD8 naïve cells were isolated by sorting T cells from the Foxp3- IRES-GFP mice: CD4+CD62LhiCD25–CD44lo GFP(FOXP3)– and CD8+CD62LhiCD25– CD44lo GFP(FOXP3)– (antibodies were from Biolegend). In some cases, naïve CD4 cells were cultured in vitro under Th1 or Th2 polarizing conditions (3, 4).
    [Show full text]
  • Multi-Targeted Mechanisms Underlying the Endothelial Protective Effects of the Diabetic-Safe Sweetener Erythritol
    Multi-Targeted Mechanisms Underlying the Endothelial Protective Effects of the Diabetic-Safe Sweetener Erythritol Danie¨lle M. P. H. J. Boesten1*., Alvin Berger2.¤, Peter de Cock3, Hua Dong4, Bruce D. Hammock4, Gertjan J. M. den Hartog1, Aalt Bast1 1 Department of Toxicology, Maastricht University, Maastricht, The Netherlands, 2 Global Food Research, Cargill, Wayzata, Minnesota, United States of America, 3 Cargill RandD Center Europe, Vilvoorde, Belgium, 4 Department of Entomology and UCD Comprehensive Cancer Center, University of California Davis, Davis, California, United States of America Abstract Diabetes is characterized by hyperglycemia and development of vascular pathology. Endothelial cell dysfunction is a starting point for pathogenesis of vascular complications in diabetes. We previously showed the polyol erythritol to be a hydroxyl radical scavenger preventing endothelial cell dysfunction onset in diabetic rats. To unravel mechanisms, other than scavenging of radicals, by which erythritol mediates this protective effect, we evaluated effects of erythritol in endothelial cells exposed to normal (7 mM) and high glucose (30 mM) or diabetic stressors (e.g. SIN-1) using targeted and transcriptomic approaches. This study demonstrates that erythritol (i.e. under non-diabetic conditions) has minimal effects on endothelial cells. However, under hyperglycemic conditions erythritol protected endothelial cells against cell death induced by diabetic stressors (i.e. high glucose and peroxynitrite). Also a number of harmful effects caused by high glucose, e.g. increased nitric oxide release, are reversed. Additionally, total transcriptome analysis indicated that biological processes which are differentially regulated due to high glucose are corrected by erythritol. We conclude that erythritol protects endothelial cells during high glucose conditions via effects on multiple targets.
    [Show full text]
  • Mucosal Effects of Tenofovir 1%
    RESEARCH ARTICLE elifesciences.org Mucosal effects of tenofovir 1% gel Florian Hladik1,2,3*, Adam Burgener4,5†, Lamar Ballweber3†, Raphael Gottardo3,6,7, Lucia Vojtech1, Slim Fourati8, James Y Dai6,7, Mark J Cameron8, Johanna Strobl3, Sean M Hughes1, Craig Hoesley9, Philip Andrew10, Sherri Johnson10, Jeanna Piper11, David R Friend12, T Blake Ball4,5, Ross D Cranston13,14, Kenneth H Mayer15, M Juliana McElrath2,3,16, Ian McGowan13,14* 1Department of Obstetrics and Gynecology, University of Washington, Seattle, United States; 2Department of Medicine, University of Washington, Seattle, United States; 3Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, United States; 4Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada; 5National HIV and Retrovirology Laboratories, Public Health Agency of Canada, Winnipeg, Canada; 6Department of Biostatistics, University of Washington, Seattle, United States; 7Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, United States; 8Vaccine and Gene Therapy Institute of Florida, Port Saint Lucie, United States; 9Department of Medicine, University of Alabama, Birmingham, United States; 10FHI 360, Durham, United States; 11Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States; 12CONRAD, Eastern Virginia Medical School, Arlington, United States; 13University of Pittsburgh School of Medicine, Pittsburgh, United States; 14Microbicide Trials Network, Magee-Women’s Research Institute, Pittsburgh, United States; 15Fenway Health, Beth Israel Deaconess Hospital, Harvard Medical School, Boston, United States; 16Department of Global Health, University of Washington, Seattle, United States *For correspondence: fhladik@ fhcrc.org (FH); mcgowanim@ mwri.magee.edu (IMG) †These authors contributed Abstract Tenofovir gel is being evaluated for vaginal and rectal pre-exposure prophylaxis against equally to this work HIV transmission.
    [Show full text]